Latest Revenue Growth News

Stakk Limited has secured a strategic multi-year partnership with Stride Bank, a 110-year-old U.S. institution, further accelerating its annualised recurring revenue and broadening its footprint across American financial sectors.

Ava Risk Group announces the upcoming retirement of CEO Mal Maginnis, with senior executive Neville Joyce appointed as Acting CEO. The company embarks on a global search for a permanent replacement amid strong recent growth.

Sonic Healthcare has reaffirmed its FY2026 EBITDA guidance with up to 13% growth, reported solid FY2025 financial results, and announced a strategic acquisition in Germany alongside notable sustainability progress.

Hansen Technologies reported robust FY25 results driven by double-digit revenue growth, strategic contract wins, and a transformative acquisition of UK-based Digitalk. The company’s integration of AI and sustainability initiatives underpin a confident outlook for sustained growth.

Dataworks Limited solidifies its leadership in regulated gaming technology with its Centralised Self-Exclusion platform, backed by major government contracts and a robust growth pipeline.

Apiam Animal Health reported a challenging FY25 with underperformance in its core clinical segment but has rebounded strongly in Q1 FY26. The company is now poised for acquisition by Adamantem Capital, offering shareholders a premium cash and scrip deal.

Activeport Group has signed nine new channel partners for its Global Edge platform, boosting its recurring revenue potential and challenging legacy players in Australia’s enterprise networking market.

EVZ Limited has issued earnings guidance for the first half of FY2026, forecasting revenue between $60 million and $65 million and a notable rise in EBITDA, reflecting operational improvements.

Turners Automotive Group has posted a resilient and record first-half result for FY26, with net profit before tax up 13% despite ongoing economic challenges. The company’s diversified model and strategic capital moves underpin its confident outlook.

AFT Pharmaceuticals reports a robust 33% revenue increase in the first half of FY26, driven by strong ANZ market performance and expanding international presence. The company advances its R&D pipeline and targets NZ$300 million revenue for FY27 amid strategic global expansion.

AFT Pharmaceuticals delivered a robust first half for FY26, posting 33% revenue growth and a return to profitability, driven by strong Australian sales and recovery in Asia and international markets. The company is advancing its global footprint and R&D pipeline, positioning for sustained growth.

AFT Pharmaceuticals has reported a robust first half of FY26, posting a 33% revenue increase to a record $114.9 million and returning to profitability amid strong growth in Australia and international markets. The company’s advancing R&D pipeline and strategic licensing deals position it well for ambitious FY27 targets.